In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma. Lymphomas DLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCT FL: Tisa-cel (ELARA), axi-cel (ZUMA-5) MZL: Liso-cel (TRANSCEND FL) MCL: Real-world outcomes post brexu-cel CLL: Liso-cel (TRANSCEND CLL 004) Multiple Myeloma Cilta-cel (CARTITUDE-1) Anito-cel (iMMagine-1) GC012F Arlo-cel BMS-986453 TriPRIL Presenters: Brad Kahl, MD Professor of Medicine Washington University St Louis, Missouri Noopur Raje, MD Director, Center for Multiple Myeloma Massachusetts General Hospital Cancer Center Professor of Medicine Harvard Medical School Boston, Massachusetts Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb. Link to full program: https://bit.ly/3ViR62V Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
